drugset / Trial / NCT00386815

Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

NCT00386815 ↗

Phase 2 Completed 20 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate safety of pemetrexed combined with cisplatin for chemo therapy-naive patients with malignant pleural mesothelioma

Timeline

Start
2006-10
Primary completion
—
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified — —
Subject Pemetrexed Small molecule — —